1. Guest editorial

   • Michael Keating
   • Michael Hallek

   EditorialNotes Pages: S1 - S2

2. A personal history of the CAMPATH-1H antibody

   • Herman Waldmann

   Original Article Pages: S3 - S9

3. Current and developing chemotherapy for CLL

   • Emili Montserrat

   Original Article Pages: S11 - S19

4. Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia

   • Anders Osterborg
   • Hakan Mellstedt
   • Michael Keating

   Original Article Pages: S21 - S26

5. Alemtuzumab in T-cell malignancies

   • Claire E. Dearden
   • Estella Matutes
   • Daniel Catovsky

   Original Article Pages: S27 - S32

6. Alemtuzumab in stem cell transplantation

   • Geoff Hale

   Original Article Pages: S33 - S47

7. Immunological effects and safe administration of alemtuzumab (MabCampath™) in advanced B-CLL

   • Ben Kennedy
   • Peter Hillmen

   Original Article Pages: S49 - S55

8. Future prospects for alemtuzumab (MabCampath™)

   • Kanti Rai
   • Michael Hallek

   Original Article Pages: S57 - S63